New animal research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Ohio Attorney General Dave Yost sent letters to 14 medical spas warning them to stop making false or misleading claims about ...